Nova Mentis Life Science Corp NMLSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.06
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $1.69 Mil
- Volume/Avg
- 6,300 / 53,834
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 79.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.novamentis.ca
Valuation
|
Metric
|
NMLSF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 79.62 |
Price/Cash Flow | — |
Price/Earnings
NMLSF
Financial Strength
|
Metric
|
NMLSF
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.06 |
Interest Coverage | — |
Quick Ratio
NMLSF
Profitability
|
Metric
|
NMLSF
|
|---|---|
Return on Assets (Normalized) | −241.12% |
Return on Equity (Normalized) | −1,608.35% |
Return on Invested Capital (Normalized) | −1,768.11% |
Return on Assets
NMLSF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hndhmxvb | Zsjdp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vznrzcw | Csrrvpn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yjjsbphr | Lzpxv | $97.8 Bil | |
MRNA
| Moderna Inc | Fphwpkyf | Ybzz | $38.8 Bil | |
ARGX
| argenx SE ADR | Plwwcss | Bfdgc | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Vdxhcvpw | Kvvg | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzbprpzzz | Nxbnfx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hzqkcpsfl | Nsnrbvl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jkcrmpcf | Dqkkdk | $12.5 Bil | |
INCY
| Incyte Corp | Wpygmtm | Zbddnsd | $11.5 Bil |